<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33380/2305-2066-2022-11-2-174-179</article-id><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-1232</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ДОКЛИНИЧЕСКИЕ И КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PRECLINICAL AND CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Изучение роли гепарина в регуляции морфофункциональных свойств МСК in vitro</article-title><trans-title-group xml:lang="en"><trans-title>Study of the Role of Heparin in Regulation of the Morphofunctional Properties of MSC in Vitro</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5212-2435</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Норкин</surname><given-names>И. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Norkin</surname><given-names>I. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>236041, г. Калининград, ул. Гайдара, 6</p></bio><bio xml:lang="en"><p>6, Gaidar str., Kaliningrad, 236041</p></bio><email xlink:type="simple">norkin_igor@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6146-3330</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Юрова</surname><given-names>К. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Yurova</surname><given-names>K. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>236041, г. Калининград, ул. Гайдара, 6</p></bio><bio xml:lang="en"><p>6, Gaidar str., Kaliningrad, 236041</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5525-3529</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хазиахматова</surname><given-names>О. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Khaziakhmatova</surname><given-names>O. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>236041, г. Калининград, ул. Гайдара, 6</p></bio><bio xml:lang="en"><p>6, Gaidar str., Kaliningrad, 236041</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8987-0664</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мелащенко</surname><given-names>Е. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Melashchenko</surname><given-names>E. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>236041, г. Калининград, ул. Гайдара, 6</p></bio><bio xml:lang="en"><p>6, Gaidar str., Kaliningrad, 236041</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3437-0926</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Малашенко</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Malashchenko</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>236041, г. Калининград, ул. Гайдара, 6</p></bio><bio xml:lang="en"><p>6, Gaidar str., Kaliningrad, 236041</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0326-0409</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шункин</surname><given-names>Е. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Shunkin</surname><given-names>E. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>236041, г. Калининград, ул. Гайдара, 6</p></bio><bio xml:lang="en"><p>6, Gaidar str., Kaliningrad, 236041</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6321-7595</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Байков</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Baikov</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>634050, г. Томск, Московский тракт, д. 2</p></bio><bio xml:lang="en"><p>2, Moskovsky tract, Tomsk, 634050</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3465-8452</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хлусов</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Khlusov</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>634050, г. Томск, Московский тракт, д. 2</p></bio><bio xml:lang="en"><p>2, Moskovsky tract, Tomsk, 634050</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5231-6910</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Литвинова</surname><given-names>Л. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Litvinova</surname><given-names>L. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>236041, г. Калининград, ул. Гайдара, 6</p></bio><bio xml:lang="en"><p> 6, Gaidar str., Kaliningrad, 236041</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Центр иммунологии и клеточной биотехнологии Балтийского федерального университета им. И. Канта<country>Россия</country></aff><aff xml:lang="en">Center of Immunology and Cellular Biotechnology, Immanuel Kant Baltic Federal University<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">ФГБОУ ВО «Сибирский государственный медицинский университет» Министерства здравоохранения Российской Федерации (ФГБОУ ВО СибГМУ Минздрава России)<country>Россия</country></aff><aff xml:lang="en">Siberian State Medical University<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>30</day><month>05</month><year>2022</year></pub-date><volume>11</volume><issue>2</issue><fpage>174</fpage><lpage>179</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Норкин И.К., Юрова К.А., Хазиахматова О.Г., Мелащенко Е.С., Малашенко В.В., Шункин Е.О., Байков А.Н., Хлусов И.А., Литвинова Л.С., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Норкин И.К., Юрова К.А., Хазиахматова О.Г., Мелащенко Е.С., Малашенко В.В., Шункин Е.О., Байков А.Н., Хлусов И.А., Литвинова Л.С.</copyright-holder><copyright-holder xml:lang="en">Norkin I.K., Yurova K.A., Khaziakhmatova O.G., Melashchenko E.S., Malashchenko V.V., Shunkin E.O., Baikov A.N., Khlusov I.A., Litvinova L.S.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/1232">https://www.pharmjournal.ru/jour/article/view/1232</self-uri><abstract><sec><title>Введение</title><p>Введение. Искусственные материалы, применяемые в регенеративной медицине, при имплантации индуцируют развитие сбалансированной воспалительной реакции, что является ключевым этапом для эффективной регенерации поврежденной костной ткани. Контакт имплантата с тканями и биологическими жидкостями сопровождается осаждением белков крови на его поверхности, что способствует активации системы комплемента и инициирует коагуляционный гемостаз, приводящий к образованию фибринового сгустка. На поверхности имплантата фибрин обеспечивает адгезию стволовых клеток, их созревание в фибробласты, продуцирующие коллаген и его производные. Образующийся внеклеточный матрикс лежит в основе формирования тканевой структуры (костной мозоли). Для предотвращения развития постоперационных патологических состояний, вызванных гиперкоагуляционным синдромом, используют терапевтические стратегии с применением антикоагулянтов, таких как гепарин. Однако их использование ограничивает образование сгустка фибрина in vivo, что может замедлять миграцию мультипотентных мезенхимальных стромальных клеток (ММСК) и последующее формирование костной мозоли.</p></sec><sec><title>Цель</title><p>Цель. Изучение влияния гепарина в фармакологических концентрациях на «стволовость» и способность ММСК жировой ткани человека к остеогенной дифференцировке в условиях культивирования in vitro.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Для оценки морфофункционального состояния клеток, культивируемых в присутствии гепарина, было сформировано 2 экспериментальные группы: 1) ММСК в присутствии гепарина в терапевтической концентрации (1,3 МЕ/мл); 2) ММСК в присутствии гепарина в токсической концентрации (13 МЕ/мл).</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. По результатам проточной цитометрии было выявлено, что добавление гепарина в обеих используемых в исследовании концентрациях в культуру ММСК приводит к увеличению числа клеток, экспрессирующих поверхностные маркеры CD73 и CD90, что свидетельствует о сохранении их стволового состояния. С другой стороны, выявлено стимулирующее действие гепарина также в обеих используемых концентрациях на транскрипцию в ММСК мРНК генов остеодифференцировки (BMP2, BMP6, ALPL, RUNX2, BGLAP и SMURF1), что может указывать на остеогенный потенциал гепарина для исследуемой культуры клеток.</p></sec><sec><title>Заключение</title><p>Заключение. Результаты исследования полезны для регенеративной медицины, связанной с использованием ММСК в клинической практике; могут служить предпосылкой для разработки новых терапевтических стратегий для пациентов ортопедотравматологического профиля с высоким риском развития послеоперационных тромбозов после проведения эндопротезирования и остеосинтеза.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Artificial materials used in regenerative medicine induce a balanced inflammatory response after implantation, which is an important step for effective regeneration of damaged bone tissue. The contact of the implant with tissues and biological fluids is accompanied by the deposition of blood proteins on its surface, which contributes to the activation of the complement system and initiates blood clotting, leading to the formation of a fibrin clot. On the surface of the implant, fibrin ensures the adhesion of stem cells and their maturation into fibroblasts that produce collagen and its derivatives. The formed extracellular matrix is the basis for the formation of a tissue structure (callus). To prevent the development of postoperative pathological conditions caused by hypercoagulatory syndrome, therapeutic strategies with anticoagulants such as heparin are used. However, their use limits the formation of a fibrin clot in vivo, which may slow down the migration of mesenchymal stromal cells (MSCs) and the subsequent formation of callus.</p></sec><sec><title>Aim</title><p>Aim. To investigate of the effect of heparin at pharmacological concentrations on stemness and the ability of MSCs from human adipose tissue to undergo osteogenic differentiation under conditions of in vitro cultivation.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. To assess the morphofunctional state of cells cultured in the presence of heparin, 2 experimental groups were formed: 1) MSCs in the presence of heparin at a therapeutic concentration (1.3 IU/ml); 2) MSCs in the presence of heparin at a toxic concentration (13 IU/ml).</p></sec><sec><title>Results and discussion</title><p>Results and discussion. Flow cytometry results showed that the addition of heparin at both concentrations used in the study to MSC culture leads to an increase in the number of cells expressing the surface markers CD73 and CD90, indicating the maintenance of their stem state. On the other hand, a stimulatory effect of heparin at both concentrations used on the transcription of mRNA of osteogenic genes (BMP2, BMP6, ALPL, RUNX2, BGLAP and SMURF1) in MSCs was also observed, which may indicate the osteogenic potential of heparin for the cell culture studied.</p></sec><sec><title>Conclusion</title><p>Conclusion. The results of the study are useful for regenerative medicine related to the use of MSCs in clinical practice; they may serve as a prerequisite for the development of new therapeutic strategies for orthopedic and traumatologic patients at high risk of postoperative thrombosis after endoprosthetics surgery and osteosynthesis.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>МСК</kwd><kwd>гепарин</kwd><kwd>in vitro</kwd><kwd>экспрессия генов остеодифференцировки</kwd><kwd>маркеры стволовости</kwd></kwd-group><kwd-group xml:lang="en"><kwd>MSC</kwd><kwd>heparin</kwd><kwd>in vitro</kwd><kwd>expression of osteodifferentiation genes</kwd><kwd>markers of stemness</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Labarrere C. A., Dabiri A. E., Kassab G. S. Thrombogenic and Inflammatory Reactions to Biomaterials in Medical Devices. Frontiers in Bioengineering and biotechnology. 2020;8:23. DOI: 10.3389/fbioe.2020.00123.</mixed-citation><mixed-citation xml:lang="en">Labarrere C. A., Dabiri A. E., Kassab G. S. Thrombogenic and Inflammatory Reactions to Biomaterials in Medical Devices. Frontiers in Bioengineering and biotechnology. 2020;8:23. DOI: 10.3389/fbioe.2020.00123.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Gorbet M. B., Sefton M. V. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials. 2004;25(26):5681–5703. DOI: 10.1016/j.biomaterials.2004.01.023.</mixed-citation><mixed-citation xml:lang="en">Gorbet M. B., Sefton M. V. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials. 2004;25(26):5681–5703. DOI: 10.1016/j.biomaterials.2004.01.023.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Chen Q. Potential role for heparan sulfate proteoglycans in regulation of transforming growth factor-beta (TGF-beta) by modulating assembly of latent TGF-beta-binding protein-1. Journal of Biological Chemistry. 2007;282(36):26418–26430. DOI: 10.1074/jbc.M703341200.</mixed-citation><mixed-citation xml:lang="en">Chen Q. Potential role for heparan sulfate proteoglycans in regulation of transforming growth factor-beta (TGF-beta) by modulating assembly of latent TGF-beta-binding protein-1. Journal of Biological Chemistry. 2007;282(36):26418–26430. DOI: 10.1074/jbc.M703341200.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ling L. Synergism between Wnt3a and Heparin Enhances Osteogenesis via a Phosphoinositide 3-Kinase/Akt/RUNX2 Pathway. Journal of Biological Chemistry. 2010;285(34):26233–26244. DOI: 10.1074/jbc.M110.122069.</mixed-citation><mixed-citation xml:lang="en">Ling L. Synergism between Wnt3a and Heparin Enhances Osteogenesis via a Phosphoinositide 3-Kinase/Akt/RUNX2 Pathway. Journal of Biological Chemistry. 2010;285(34):26233–26244. DOI: 10.1074/jbc.M110.122069.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Christodoulou I., Goulielmaki M., Devetzi M., Panagiotidis M., Koliakos G., Zoumpourlis V. Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review. Stem Cell Research &amp; Therapy. 2018;9(336). DOI: 10.1186/s13287-018-1078-8.</mixed-citation><mixed-citation xml:lang="en">Christodoulou I., Goulielmaki M., Devetzi M., Panagiotidis M., Koliakos G., Zoumpourlis V. Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review. Stem Cell Research &amp; Therapy. 2018;9(336). DOI: 10.1186/s13287-018-1078-8.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ali H., Al-Yatama M. K., Abu-Farha M., Behbehani K., Al Madhoun A. Multi-Lineage Differentiation of Human Umbilical Cord Wharton’s Jelly Mesenchymal Stromal Cells Mediates Changes in the Expression Profile of Stemness Markers. PLoS One. 2015;10(4). DOI: 10.1371/journal.pone.0122465.</mixed-citation><mixed-citation xml:lang="en">Ali H., Al-Yatama M. K., Abu-Farha M., Behbehani K., Al Madhoun A. Multi-Lineage Differentiation of Human Umbilical Cord Wharton’s Jelly Mesenchymal Stromal Cells Mediates Changes in the Expression Profile of Stemness Markers. PLoS One. 2015;10(4). DOI: 10.1371/journal.pone.0122465.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Moraes. D. A. A reduction in CD90 (THY-1) expression results in increased differentiation of mesenchymal stromal cells. Stem Cell Research &amp; Therapy. 2016; 7. DOI: 10.1186/s13287-016-0359-3.</mixed-citation><mixed-citation xml:lang="en">Moraes. D. A. A reduction in CD90 (THY-1) expression results in increased differentiation of mesenchymal stromal cells. Stem Cell Research &amp; Therapy. 2016; 7. DOI: 10.1186/s13287-016-0359-3.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Sun Q., Nakata H., Yamamoto M., Kasugai S., Kuroda S. Comparison of gingiva‐derived and bone marrow mesenchymal stem cells for osteogenesis. Journal of Cellular and Molecular Medicine. 2019;23(11):7592–7601. DOI: 10.1111/jcmm.14632.</mixed-citation><mixed-citation xml:lang="en">Sun Q., Nakata H., Yamamoto M., Kasugai S., Kuroda S. Comparison of gingiva‐derived and bone marrow mesenchymal stem cells for osteogenesis. Journal of Cellular and Molecular Medicine. 2019;23(11):7592–7601. DOI: 10.1111/jcmm.14632.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Picke A. K. Thy-1 (CD90) promotes bone formation and protects against obesity. Science Translational Medicine. 2018;10(453). DOI: 10.1126/scitranslmed.aao6806.</mixed-citation><mixed-citation xml:lang="en">Picke A. K. Thy-1 (CD90) promotes bone formation and protects against obesity. Science Translational Medicine. 2018;10(453). DOI: 10.1126/scitranslmed.aao6806.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Netsch P. Human mesenchymal stromal cells inhibit platelet activation and aggregation involving CD73-converted adenosine. Stem Cell Research &amp; Therapy. 2018;9(1):184. DOI: 10.1186/s13287-018-0936-8.</mixed-citation><mixed-citation xml:lang="en">Netsch P. Human mesenchymal stromal cells inhibit platelet activation and aggregation involving CD73-converted adenosine. Stem Cell Research &amp; Therapy. 2018;9(1):184. DOI: 10.1186/s13287-018-0936-8.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Jang W. G. BMP2 protein regulates osteocalcin expression via Runx2-mediated Atf6 gene transcription. Journal of Biological Chemistry. 2012;287(2):905–915. DOI: 10.1074/jbc.M111.253187.</mixed-citation><mixed-citation xml:lang="en">Jang W. G. BMP2 protein regulates osteocalcin expression via Runx2-mediated Atf6 gene transcription. Journal of Biological Chemistry. 2012;287(2):905–915. DOI: 10.1074/jbc.M111.253187.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ye F. The role of BMP6 in the proliferation and differentiation of chicken cartilage cells. PLoS One. 2019;14(7). DOI: 10.1371/journal.pone.0204384.</mixed-citation><mixed-citation xml:lang="en">Ye F. The role of BMP6 in the proliferation and differentiation of chicken cartilage cells. PLoS One. 2019;14(7). DOI: 10.1371/journal.pone.0204384.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Cai C., Wang J., Huo N., Wen L., Xue P., Huang Y. Msx2 plays an important role in BMP6-induced osteogenic differentiation of two mesenchymal cell lines: C3H10T1/2 and C2C12. Regenerative Therapy. 2020;14:45–251. DOI: 10.1016/j.reth.2020.03.015.</mixed-citation><mixed-citation xml:lang="en">Cai C., Wang J., Huo N., Wen L., Xue P., Huang Y. Msx2 plays an important role in BMP6-induced osteogenic differentiation of two mesenchymal cell lines: C3H10T1/2 and C2C12. Regenerative Therapy. 2020;14:45–251. DOI: 10.1016/j.reth.2020.03.015.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Li J. Z. Osteogenic potential of five different recombinant human bone morphogenetic protein adenoviral vectors in the rat. Gene therapy. 2003;10(20): 1735–1743. DOI: 10.1038/sj.gt.3302075.</mixed-citation><mixed-citation xml:lang="en">Li J. Z. Osteogenic potential of five different recombinant human bone morphogenetic protein adenoviral vectors in the rat. Gene therapy. 2003;10(20): 1735–1743. DOI: 10.1038/sj.gt.3302075.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ofiteru A. M. Qualifying Osteogenic Potency Assay Metrics for Human Multipotent Stromal Cells: TGF-β2 a Telling Eligible Biomarker. Cells. 2020;9(12):2559. DOI: 10.3390/cells9122559.</mixed-citation><mixed-citation xml:lang="en">Ofiteru A. M. Qualifying Osteogenic Potency Assay Metrics for Human Multipotent Stromal Cells: TGF-β2 a Telling Eligible Biomarker. Cells. 2020;9(12):2559. DOI: 10.3390/cells9122559.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Kannan S., Ghosh J., Dhara S. K. Osteogenic differentiation potential of porcine bone marrow mesenchymal stem cell subpopulations selected in different basal media. Biology Open. 2020;9(10). DOI: 10.1242/bio.053280.</mixed-citation><mixed-citation xml:lang="en">Kannan S., Ghosh J., Dhara S. K. Osteogenic differentiation potential of porcine bone marrow mesenchymal stem cell subpopulations selected in different basal media. Biology Open. 2020;9(10). DOI: 10.1242/bio.053280.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu B., Xue F., Zhang C., Li G. LMCD1 promotes osteogenic differentiation of human bone marrow stem cells by regulating BMP signaling. Cell Death &amp; Disease. 2019;10(9):647. DOI: 10.1038/s41419-019-1876-7.</mixed-citation><mixed-citation xml:lang="en">Zhu B., Xue F., Zhang C., Li G. LMCD1 promotes osteogenic differentiation of human bone marrow stem cells by regulating BMP signaling. Cell Death &amp; Disease. 2019;10(9):647. DOI: 10.1038/s41419-019-1876-7.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
